Sign in

The Lancet Medical Imaging & Theranostics

@lancetimaging.bsky.social
132 followers 340 following 50 posts

A gold OA journal dedicated to clinical and technological advances in radiology, nuclear medicine, and theranostics. 🌐 www.thelancet.com/medical-imaging-theranostics

PostsRepliesMedia
The Lancet Medical Imaging & Theranostics @lancetimaging.bsky.social · 6h
📈Read one of our editor picks for September I Von Polenz, F Giammarile & L Mansi recommend to integrate radiotheranostics into national cancer planning to avoid widening cancer survival gaps. www.thelancet.com/journals/lan...
thelancet.com
Integrating radiotheranostics into national cancer planning to avoid widening cancer survival gaps: the case for equity-adjusted value
Radiotheranostics, which integrates molecular imaging with targeted radionuclide therapy, has progressed from proof of concept to clinical standard faster than most national cancer plans have kept pac...
010
The Lancet Medical Imaging & Theranostics @lancetimaging.bsky.social · 01/10/2026
💡3rd highlight from our Sept issue G Lemmens & coll from U of Aachen, UCL, Human Atlas Hub, ESRF, U of Antwerp & Gottingen present a review of hierarchical phase-contrast tomography, an imaging modality that bridges the gap between histology and radiology Read it 🔓 bit.ly/47pARa2
bit.ly
Hierarchical phase-contrast tomography: synchrotron x-ray imaging bridges the gap between histology and radiology
Conventional radiological imaging techniques provide comprehensive anatomical and functional views across the whole body but do not have adequate resolution to visualise smaller-sized structures withi...
111
The Lancet Medical Imaging & Theranostics @lancetimaging.bsky.social · 30/09/2026
🔦2nd highlight from our Sept issue A Chirindel & coll from University hospital of Basel report on the evaluation of the safety and clinical activity of [177Lu]Lu-PSMA-I&T in routine practice. Read their study 🔓 bit.ly/4AApMAi #medsky #radsky #prostatecancer
bit.ly
PSMA-targeted radioligand therapy with [177Lu]Lu-PSMA-I&T in metastatic castration-resistant prostate cancer: a prospective, multicentre, Swiss registry study
[177Lu]Lu-PSMA-I&T showed clinically meaningful activity with a favourable safety profile in heavily pretreated mCRPC. These findings provide prospective evidence supporting the safety and activity of...
010
The Lancet Medical Imaging & Theranostics @lancetimaging.bsky.social · 29/09/2026
💡First highlight from our Sept issue J Ruffle & coll from @ucl.ac.uk propose an AI tool to predict tumor enhancement from non contrast #MRI Read it 🔓 bit.ly/4iUrXbF #neurosky
110
The Lancet Medical Imaging & Theranostics @lancetimaging.bsky.social · 28/09/2026
🎉Our September issue is now live Prostate cancer, brain tumor, HiP-CT and more... Read it all here ➡️ www.thelancet.com/journals/lan... As a gold open access journal, our content is free to read by everyone, always. #OA #MedSky #RadSky
Cinematic rendering of a HiP-CT scan at Beamline BM18 (European Synchrotron Radiation Facility, France), showing the bronchial and vascular system of a human lung (Cinematic Anatomy, Siemens Healthineers, Germany).
010
The Lancet Medical Imaging & Theranostics @lancetimaging.bsky.social · 22/09/2026
🎧NEW podcast episode: C Walsh, director of the Human Organ Atlas Hub and G Lemmens, PhD candidate @rwth.bsky.social discussed their review, explained the HiP-CT technique and shared exciting new prospects for this imaging modality. www.thelancet.com/audio-do/cla...
thelancet.com
Claire Walsh and Giel Lemmens on Hierarchical Phase Contrast Computed Tomography
Did you know we can image whole organs in 3D at multiple scales? The modality that enables this is called Hierarchical Phase Contrast Computed Tomography (HiP-CT). Claire Walsh, a Principle Research F...
120
Reposted by The Lancet Medical Imaging & Theranostics
Samia Mohinta @mohintasamia.bsky.social · 19/09/2026
Our latest work on how AI could predict contrast enhancement in brain tumours from non-contrast MRI is now published at @lancetimaging.bsky.social: www.thelancet.com/journals/lan... A huge thank you to all co-authors and funders!!
011
Reposted by The Lancet Medical Imaging & Theranostics
The Lancet @thelancet.com · 16/09/2026
A new AI tool could help doctors avoid unnecessary contrast-dye injections for some brain tumour patients, according to a study in @lancetimaging.bsky.social Explore the research 👉 tinyurl.com/2uufu6ur
tinyurl.com
Predicting brain tumour enhancement from non-contrast MRI with artificial intelligence: a multicohort, retrospective, diagnostic accuracy study
Deep learning can identify contrast-enhancing brain tumours from non-contrast MRI. These models show promise as a triage or decision-support aid—for example, flagging studies in which post-contrast en...
1157
The Lancet Medical Imaging & Theranostics @lancetimaging.bsky.social · 10/09/2026
Our first editorial, in our August issue, presents our vision and hopes for the new journal. We are all looking forward working with researchers & clinicians to advance imaging and improve health. Read bit.ly/3VmfOSY
012
The Lancet Medical Imaging & Theranostics @lancetimaging.bsky.social · 03/09/2026
3rd highlight from our August issue M Dremmen & coll from Erasmus University of Rotterdam present population-based neuroimaging growth curves for children and young adults. Read bit.ly/4yi81Uq #neurosky #pedsky
bit.ly
Neuroimaging growth curves in children and young adults aged 6–20 years in the Netherlands: a population-based cohort substudy of the Generation R Study
The developed growth curves provide a quantitative reference framework for paediatric brain development and identify subtle but clinically relevant deviations in specific patient groups, and have the ...
110
The Lancet Medical Imaging & Theranostics @lancetimaging.bsky.social · 02/09/2026
2nd highlight from our August issue C Lei & coll from Nanjing University evaluated the potential of [18F]FDG-PET–CT-defined complete metabolic response (CMR) to provides complementary prognostic information for patients with renal carcinoma Read bit.ly/4x3RtPe #PET #CT #oncsky #cansky #radsky
bit.ly
Prognostic value of 1-year [18F]FDG-PET–CT-defined complete metabolic response in metastatic clear-cell renal cell carcinoma: a multicentre, observational cohort study in China
In patients with mccRCC who remained progression free throughout the first year of first-line ICB-based therapy, 1-year [18F]FDG-PET–CT-defined CMR provided clinically relevant prognostic stratificati...
100
The Lancet Medical Imaging & Theranostics @lancetimaging.bsky.social · 01/09/2026
1st highlight from our August issue H Einspieler & coll present a secondary analysis of the phase 3 RAPID trial evaluating the potential value of PSMA PET-CT for prostate cancer diagnosis. Read bit.ly/4zQsK3h #PET #prostatecancer #openaccess
Representative case of clinically significant prostate cancer
100
Reposted by The Lancet Medical Imaging & Theranostics
The Lancet Respiratory Medicine @lancetrespirmed.bsky.social · 26/08/2026
🫁 Explore our September 2026 issue, out now in print and online! 🔗 www.thelancet.com/issue/S2213-... 🔹 This issue covers postoperative pulmonary complications, #NSCLC, pulmonary fibrosis of childhood #ILD and much more
Alt: In a children’s activity room, a pair of glass windows forms the shape of lungs, with dust covering the surface to represent pulmonary fibrosis. A child wipes away the dust and reveals other children outside the windows, symbolising the progress made through research and highlighting the need to bring greater attention to children affected by these conditions.

Credit: Lillian Li
001
Reposted by The Lancet Medical Imaging & Theranostics
The Lancet Gastroenterology & Hepatology @lancetgastrohep.bsky.social · 09/07/2026
The August 2026 issue of @lancetgastrohep.bsky.social hep.bsky.social is out now at www.thelancet.com/gastrohep! Content includes #pancreaticcancer, #IBD, eosinophilic #gastritis, #livercancer, #MASLD + more! #GastroSky #LiverSky #MedSky
032
Reposted by The Lancet Medical Imaging & Theranostics
The Lancet Gastroenterology & Hepatology @lancetgastrohep.bsky.social · 17/07/2026
🆕Artificial intelligence-assisted detection and optical differentiation of colorectal lesions in Lynch syndrome surveillance (CADLY2): a multicentre, open-label, randomised controlled superiority trial www.thelancet.com/journals/lan... #GastroSky #OncSky #MedSky #AI
thelancet.com
Artificial intelligence-assisted detection and optical differentiation of colorectal lesions in Lynch syndrome surveillance (CADLY2): a multicentre, open-label, randomised controlled superiority trial
CADe-assisted colonoscopy did not show the absolute improvement in adenoma detection rate that was assumed in the prespecified sample-size calculation. CADx did not clearly improve lesion differentiat...
022
Reposted by The Lancet Medical Imaging & Theranostics
The Lancet Rheumatology @thelancetrheum.bsky.social · 21/07/2026
Our August 2026 issue is live! Including research on sacroiliac joint #bonemarrowoedema, a precision medicine tool in #Sjögrens disease, the role of #healthliteracy in #inflammatoryarthritis, plus much more! thelancet.com/journals/lanrhe/home Cover by @emma-cheng.bsky.social #Medsky #Rheumsky
065
Reposted by The Lancet Medical Imaging & Theranostics
The Lancet @thelancet.com · 23/07/2026
🔔 Discover The Lancet Surgery & Anaesthesiology, a new journal with a sharp clinical focus, dedicated to advancing science across the full extent of #surgery, #anaesthesiology, and #perioperative specialties, across the age spectrum, and across the globe: spkl.io/633237JQbc
Illustration of a female in green scrubs, cap, and blue surgical mask, surrounded by four smaller illustrations showing surgical instruments and operating room scenes. Copyright: Grace Russell.
1710
Reposted by The Lancet Medical Imaging & Theranostics
The Lancet Oncology @thelancetoncol.bsky.social · 25/08/2026
🆕Our Sept issue is now live! 📊Articles: #hepatocellularcarcinoma #NSCLC #rectalcancer #breastcancer #prostatecancer 📉Featuring trials: EMERALD-3, HARMONi, ALINA, STAR-TREC, & GETUG AFU 18 🎨Cover: breast cancer, TILs, and AI 🖱️Read here: www.thelancet.com/issue/S1470-...
003
Reposted by The Lancet Medical Imaging & Theranostics
eClinicalMedicine – The Lancet Discovery Science @eclinicalmed.bsky.social · 24/08/2026
📢NEW: August issue now online featuring #HepB, #MS, #BreastCancer, #Psoriasis, #COVID, #Psychosis, #MacularOedema, and more, with our editorial on #heatwaves and health system resilience …all available #free, #OpenAccess❗️ Read here: www.thelancet.com/issue/S2589-... Attribution: Getty #MedSky
015
Reposted by The Lancet Medical Imaging & Theranostics
The Lancet @thelancet.com · 22/08/2026
We're inviting submissions for the 2025 #WakleyPrize Essay Competition. ✍️ Explore this year's theme, put pen to paper, and submit your work today: spkl.io/633267zgsE
Promotional card for The Lancet's Wakley Prize Essay Competition. Text on card reads: The Wakley Prize Essay Competition: A call for submissions. Background image is of Thomas Wakley, who founded The Lancet in 1823.
055
The Lancet Medical Imaging & Theranostics @lancetimaging.bsky.social · 27/08/2026
📢 We’ve published our first issue! Read and download our inaugural issue here ➡️ www.thelancet.com/issue/S3117-... Thank you to our authors and reviewers for their valuable contributions ✨ As a gold open access journal, our content is free to read by everyone, always. #OA #MedSky #RadSky
Image ALT text: Representative images of individuals with different NMN BBB scores. The left column shows contrast enhanced MRI brain scans and the right column shows the fusion of the MRI scans and PET scans of these same individuals.  The top row corresponds to an individual with a NMN BBB score of 2 as minor parts of PET-positive volume show contrast enhancement on MRI. The bottom row corresponds to an individual with a NMN BBB score of 5 as the PET positive volume shows complete contrast enhancement on MRI. 
Copyright: The authors, Nathalie Albert and colleagues. Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
178
The Lancet Medical Imaging & Theranostics @lancetimaging.bsky.social · 27/08/2026
📢 We’ve published our first issue! Thank you to our authors and reviewers for their valuable contributions ✨ As a #goldopenaccess journal, our content is free to read by everyone, always. Read and download our inaugural issue here ➡️ bit.ly/4y6p9wt #MedSky #RadSky
Representative images of individuals with different NMN BBB scores. The left column shows contrast enhanced MRI brain scans and the right column shows the fusion of the MRI scans and PET scans of these same individuals.  The top row corresponds to an individual with a NMN BBB score of 2 as minor parts of PET-positive volume show contrast enhancement on MRI. The bottom row corresponds to an individual with a NMN BBB score of 5 as the PET positive volume shows complete contrast enhancement on MRI. 
Copyright: The authors, Nathalie Albert and colleagues. Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
024
The Lancet Medical Imaging & Theranostics @lancetimaging.bsky.social · 04/08/2026
🎉Really happy to share our first original research article, ahead of our inaugural issue of the journal. @guilhermepovala.bsky.social & colleagues from the HEAD study propose a PET–CT pipeline using low-dose CT to quantify tau PET without MRI. Read #openaccess bit.ly/45KxZUg #Alzheimers #MRI #PET
084
The Lancet Medical Imaging & Theranostics @lancetimaging.bsky.social · 01/07/2026
📣 The Lancet #MedicalImaging & #Theranostics is now indexed in Crossref.  We are committed to supporting you on every stage of your publication journey. Learn more about our scope, impact, and global reach: hubs.li/Q04k_6ym0 #OpenAccess #MedSky
 The Lancet Medical Imaging & Theranostics promotional graphic: ‘Publish with us—a new open access destination for clinical and technological advances in radiology, nuclear medicine, and theranostics research.’ Copyright: Elsevier Ltd.
110
Reposted by The Lancet Medical Imaging & Theranostics
The Lancet Oncology @thelancetoncol.bsky.social · 30/06/2026
🆕Our July issue is live! 📊Articles: #NSCLC #Breastcancer #prostatecancer #glioblastoma 📉Trials: AENEAS2, SUBITO, EORTC 22922/10925, ARTO, PRIMARY2, CAIRO6, & INTRAGO-II 🎨Cover: Meta-analysis on AEs of CD3 T cell-engaging bispecific abs Read here: thelancet.com/issue/S1470-...
022
The Lancet Medical Imaging & Theranostics @lancetimaging.bsky.social · 29/06/2026
Attending #RCRGlobalAI in London? Our team, Ali Landman and Ankita Das will be there and available to discuss about our journal, your projects and potential collaborations! Feel free to reach out
011
The Lancet Medical Imaging & Theranostics @lancetimaging.bsky.social · 04/06/2026
💥 Introducing The Lancet Medical Imaging & Theranostics podcast 💥 🎙️ In our debut episode, our Editor-in-Chief is joined by Dr Preusser and @nathaliealbert.bsky.social to discuss insights from the @nmnsymposium.bsky.social. 🎧 Listen to the episode bit.ly/49F56LM
bit.ly
Nathalie Albert and Matthias Preusser on the NMN-BBB score | The Lancet Medical Imaging and Theranostics Podcast
Professor Matthias Preusser (Medical University of Vienna, Austria) and Professor Nathalie Albert (LMU University Hospital, Munich, Germany) join Editor-in-Chief Ali Landman to discuss the Nuclear Med...
101
The Lancet Medical Imaging & Theranostics @lancetimaging.bsky.social · 01/06/2026
Hope you are enjoying #SNMMI2026 and/or #ASCO2026! Feel free to reach out directly to discuss potential submissions!
010
The Lancet Medical Imaging & Theranostics @lancetimaging.bsky.social · 29/05/2026
📣 Just in time for #ASCO2026 & #SNMMI2026... Read a new Comment from Keamogetswe Ramonaheng and Mike Sathekge at NuMeRI on the crucial role of dosimetry in delivering truly personalised treatments in oncology Read for free: www.thelancet.com/journals/lan...
thelancet.com
Dosimetry as the compass of radiotheranostics: from fixed activity to true precision
Radiopharmaceutical therapy stands at a decisive crossroads. After decades of administering mostly fixed or weight-based activities (the amount of radioactivity administered to a patient),1,2 the scie...
000
Reposted by The Lancet Medical Imaging & Theranostics
The Lancet Oncology @thelancetoncol.bsky.social · 28/05/2026
Heading to #ASCO26? Reach out to Dr David Collingridge, Editor-in-Chief at @thelancetoncol.bsky.social, attending #ASCO26 🗓️ Attend the Global Oncology: A Workforce Crisis—A Lancet Oncology Commission session May 31, 2026, 4:30 PM-5:45 PM CDT #cancerworkforce meetings.asco.org/meetings/202...
012
The Lancet Medical Imaging & Theranostics @lancetimaging.bsky.social · 27/05/2026
Our deputy editor, Pierre Nauleau, will attend #AIUM the #Ultrasound conference in Philadelphia later this week. Please reach out if you want to meet and discuss your research! @aiumultrasound.bsky.social
000
Reposted by The Lancet Medical Imaging & Theranostics
The Lancet Oncology @thelancetoncol.bsky.social · 04/02/2026
🆕 Greater transparency for oncology clinical trials reporting Chief Editors of The Lancet’s specialty journals discuss enhanced scrutiny in the reporting of oncology clinical trials Read here: thelancet.com/journals/lan...
012
The Lancet Medical Imaging & Theranostics @lancetimaging.bsky.social · 13/05/2026
Hope you are enjoying the presentations at #ISMRM2026. Feel free to reach out if you would like to discuss potential submissions to the journal with the editorial team!
000
The Lancet Medical Imaging & Theranostics @lancetimaging.bsky.social · 07/05/2026
🎉Proud to share our first online article by @nathaliealbert.bsky.social & colleagues that was presented at #NMN2026 @nmnsymposium.bsky.social www.thelancet.com/action/showF...
thelancet.com
Imaging-based classification of blood–brain barrier disruption in glioblastoma for patient selection in clinical trials: the NMN-BBB score
The blood–brain barrier (BBB) limits the activity of novel treatments, such as pharmacotherapies and targeted radionuclide therapies in glioblastoma. Selection of patients with extensive tumoural BBB ...
134
The Lancet Medical Imaging & Theranostics @lancetimaging.bsky.social · 06/05/2026
📌In case you missed it📌 You can watch our webinar on Publishing Excellence with The Lancet Medical Imaging & Theranostics on demand now ➡️ hubs.li/Q042sbkM0 Many thanks to all who attended live and provided us with some great discussion points
000
The Lancet Medical Imaging & Theranostics @lancetimaging.bsky.social · 05/05/2026
Our editor in chief, Ali Landman, will attend @nmnsymposium.bsky.social in Vienna, May 7-8. Please reach out if you would like to discuss about our new journal, your research and potential collaborations! #NMN2026
Promotional card. Contact Ali Landman regarding content enquiries at allison.landman@lancet.com. Copyright: Elsevier Ltd.
010
The Lancet Medical Imaging & Theranostics @lancetimaging.bsky.social · 23/04/2026
📅 This time next week, please join us for our webinar on Publishing Excellence with The Lancet Medical Imaging & Theranostics Register here to attend live or to receive a link to the recording ➡️ hubs.li/Q042sbn40
001
The Lancet Medical Imaging & Theranostics @lancetimaging.bsky.social · 20/04/2026
📢 Join our webinar on publishing excellence on April 30, 2026, 15.00 BST/10.00 EDT Register to attend live or receive the link to the on-demand version when available ➡️https://hubs.li/Q042sbn40
000
Reposted by The Lancet Medical Imaging & Theranostics
The Lancet @thelancet.com · 06/04/2026
Retroperitoneal fibrosis is a rare immune-mediated disease which can be classified as idiopathic or secondary. A new Seminar provides an overview of retroperitoneal fibrosis focusing on pathophysiology, differential diagnosis, and management: spkl.io/63323AFbdz
[18F]-fluorodeoxyglucose-PET scans in a patient with idiopathic retroperitoneal fibrosis showing a hypermetabolic tissue surrounding the lower abdominal aorta (A: axial view & C: coronal view) & the common iliac arteries (B: axial view); the left ureter is also encased (A, C, & arrows). (D, E) CT scans in a patient with idiopathic retroperitoneal fibrosis showing the typical periaorto-iliac tissue (arrows; D: coronal view & E: sagittal view). (F, G) Contrast-enhanced CT scans of the abdomen in a patient with idiopathic retroperitoneal fibrosis showing the periaortic (F: arrow) & peri-iliac (G: arrow) tissue. (H) Contrast-enhanced CT scan of the abdomen in a patient with perianeurysmal retroperitoneal fibrosis showing a soft-tissue mass (arrow) surrounding an aneurysmal aorta; the aortic lumen is partly occupied by a large thrombus. (I) Contrast-enhanced CT scan of the abdomen in a patient with retroiliac, paravertebral idiopathic retroperitoneal fibrosis (arrow; atypical localisation).
041
The Lancet Medical Imaging & Theranostics @lancetimaging.bsky.social · 14/04/2026
📢 Have you registered yet? Register now: hubs.li/Q042sbn40 Join our editorial team as we share insights on their journal's aims and scope, what we look for in a research paper, and best practices for preparing your manuscript. #MedSky #RadSky
000
The Lancet Medical Imaging & Theranostics @lancetimaging.bsky.social · 07/04/2026
🔎 Want to learn more about the journal's aims and scope and what we are looking for in a research paper? 🎬 Join us on April 30th for a webinar on publishing excellence with The Lancet Medical Imaging & Theranostics For more information and to register see ➡️ hubs.li/Q042sbn40
000
The Lancet Medical Imaging & Theranostics @lancetimaging.bsky.social · 06/04/2026
💡 Stay connected to your field. Access our late-breaking content, Series and Commissions, and learn about our involvement at global conferences. Register for Lancet Conference Alerts today: hubs.li/Q045K7ZC0 #Radiology #MedicalImaging #Radsky
000
Reposted by The Lancet Medical Imaging & Theranostics
The Lancet @thelancet.com · 02/04/2026
🆕 Introducing The Lancet Regional Health – Eastern Mediterranean, a new #goldopenaccess journal promoting the advancement of clinical practice and health policy in the Eastern Mediterranean. Discover the new addition to The Lancet Group at: spkl.io/63328AFIyw #medsky
Promotional card announcing the launch of The Lancet Regional Health - Eastern Mediterranean. Text on card reads: Discover a new open access journal advancing clinical practice and health policy in the Eastern Mediterranean. Image depicts a woman sitting in a chair while speaking to a doctor holding an electronic tablet.
037
Reposted by The Lancet Medical Imaging & Theranostics
The Lancet Oncology @thelancetoncol.bsky.social · 02/04/2026
This month's podcast: James Nagarajah on [177Lu]-PSMA-617 in oligometastatic hormone sensitive prostate cancer (BULLSEYE): an open-label, randomised, phase 2 study 🎧 Listen & subscribe! Spotify: open.spotify.com/show/3JOj0Cl... Apple: podcasts.apple.com/us/podcast/t...
032
The Lancet Medical Imaging & Theranostics @lancetimaging.bsky.social · 23/03/2026
Have you signed up for alerts from The Lancet Medical Imaging & Theranostics yet?   Register for Table of Contents & Online First Alerts, sent monthly from when our first issue is available, or weekly for Online First content. Sign up to Journal Alerts here hubs.li/Q045JY-R0 #goldopenaccess
003
The Lancet Medical Imaging & Theranostics @lancetimaging.bsky.social · 18/03/2026
🎧NEW podcast Our editor-in-chief, Ali Landman talked with Cheryl Lai, deputy editor of @thelancetoncol.bsky.social about our journal, its scope, the team. She also shared her takeaways from the European Congress of Radiology #ECR. #RadSky
buzzsprout.com
Ali Landman on the European Congress of Radiology 2026 - The Lancet Oncology in conversation with
Join us for this special episode where Deputy Editor Cheryl Lai speaks with Ali Landman, Editor-in-Chief of The Lancet Medical Imaging & Theranostics, about the scope and vision of the new journal...
002
Reposted by The Lancet Medical Imaging & Theranostics
The Lancet Primary Care @lancetprimarycare.bsky.social · 11/03/2026
Our new issue is out now 🎉 We feature research on #bladdercancer, routine testing for detection of #syphilis, and point-of-care testing strategies for #antibioticprescribing for respiratory tract infections, and more! Explore and download the issue on our journal homepage: hubs.li/Q03yqV6c0.
The cover of The Lancet Primary Care February 2026 issue, featuring a pharmacist helping an older patient with their prescription.
132
The Lancet Medical Imaging & Theranostics @lancetimaging.bsky.social · 16/03/2026
Thinking where to submit your next manuscript? We’re inviting quality, original research in clinical and technological advances in #radiology, nuclear medicine and theranostics. APCs will be waived on accepted Articles submitted by Sep 2, 2026. Learn more: hubs.li/Q045K3jl0 #goldopenaccess
003
The Lancet Medical Imaging & Theranostics @lancetimaging.bsky.social · 13/03/2026
This Monday is the 26th Annual @roysocmed.bsky.social #PET day. Our editor in chief, Ali Landman, and our senior editor, Ankita Das will be there. Please reach out if you want to discuss about the journal, your research and potential collaborations! www.rsm.ac.uk/events/radio...
nam11.safelinks.protection.outlook.com
26th Annual RSM PET day
Explore the role of emerging tracers, the impact of artificial intelligence on PET and gain a better understanding of PET-CT in common malignancies.
000
Reposted by The Lancet Medical Imaging & Theranostics
The Lancet Microbe @lancetmicrobe.bsky.social · 12/03/2026
Our March issue is now online: www.thelancet.com/journals/lan... Our journal is #OpenAccess, so you are free to explore all of our content. But these hashtags offer a flavour: #malaria #HIV #Streptococcus #PCV #RiftValleyFever #pertussis #tuberculosis #TB #AMR #IDSky #ClinMicro #TBSky #OA
March cover of The Lancet Microbe
136